Hepatic Transcriptome Analysis of Hepatitis C Virus Infection in Chimpanzees Defines Unique Gene Expression Patterns Associated with Viral Clearance

Santosh Nanda1,3*, Michael B. Havert1,3*, Gloria M. Calderón1, Michael Thomson1,4, Christian Jacobson2,5, Daniel Kastner2, T. Jake Liang1*

1 Liver Diseases Branch, NIDDK, NIH, Bethesda, Maryland, United States of America, 2 Genetics and Genomics Branch, NIAMS, NIH, Bethesda, Maryland, United States of America, 3 CBER, FDA, Bethesda, Maryland, United States of America, 4 Virology Department, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America, 5 Departments of Biology and Mechanical & Mechatronics Engineering, University of Waterloo, Waterloo, Ontario, Canada

Abstract

Hepatitis C virus infection leads to a high rate of chronicity. Mechanisms of viral clearance and persistence are still poorly understood. In this study, hepatic gene expression analysis was performed to identify any molecular signature associated with the outcome of hepatitis C virus (HCV) infection in chimpanzees. Acutely HCV-infected chimpanzees with self-limited infection or progression to chronicity were studied. Interferon stimulated genes were induced irrespective of the outcome of infection. Early induction of a set of genes associated with cell proliferation and immune activation was associated with subsequent viral clearance. Specifically, two of the genes: interleukin binding factor 3 (ILF3) and cytotoxic granule-associated RNA binding protein (TIA1), associated with robust T-cell response, were highly induced early in chimpanzees with self-limited infection. Up-regulation of genes associated with CD8+ T cell response was evident only during the clearance phase of the acute self-limited infection. The induction of these genes may represent an initial response of cellular injury and proliferation that successfully translates to a “danger signal” leading to induction of adaptive immunity to control viral infection. This primary difference in hepatic gene expression between self-limited and chronic infections supports the concept that successful activation of HCV-specific T-cell response is critical in clearance of acute HCV infection.

Introduction

Since the identification of hepatitis C virus (HCV) in the late 1980s, HCV infection has been recognized as a growing public health problem in the world. It is estimated that about 200 million people are chronically infected [1]. No HCV vaccines are available to date and only a subset of patients respond to current interferon-based treatment [1]. Much research effort has been focused on understanding the mechanisms of infection, persistence and clearance of HCV. Studies on hepatic gene expression in chimpanzees and humans have revealed intriguing differences between acute resolving and chronic HCV infections [2-6]. In the chimpanzee model, HCV infection induces type 1 IFN response and activation of a large number of interferon stimulated genes (ISGs) in the liver [2,6,7]. However, hepatic induction of type 1 IFN occurred in all animals irrespective of the outcome of infection [6,8]. Thus, type 1 IFN may restrict excessive viral replication in the early phase of infection but does not seem to play a major role in subsequent viral clearance. Similar to experimentally infected chimpanzees, gene expression analysis of percutaneous liver biopsies in HCV infected humans demonstrated increased ISG expression, suggesting an ongoing host cellular response to viral infection [4]. It is not well understood why HCV is not cleared from these individuals despite the activation of potent antiviral ISGs. It is possible that in these individuals with viral persistence, the cellular response to IFN is inefficient compared to those who clear the virus. Weak induction of the ISG antiviral state coupled with an ineffective cellular immune response could therefore promote chronicity [3].

Studies of temporal changes in gene expression are central to understanding viral clearance, persistence and hepatic injury in chronic HCV infection. The intrahepatic T cell response to HCV correlates with control of acute infection [7]. Cytokine and immunomodulatory genes, generally known to be chemotactic and/or stimulatory to various immune cells were observed to be induced within the first 6 to 8 weeks after infection [2]. Viral clearance is associated with a vigorous HCV-specific T-cell response in the liver with both cytotoxic and non-cytotoxic effector functions. However HCV persists in the majority of acutely infected patients. The mechanisms leading to the failure of HCV-specific T-cell response and viral persistence are highly complex and still not fully understood. Therefore it is important to compare the spectrum and magnitude of hepatic gene expression in individuals who spontaneously clear infection and those who progress to chronicity. In this study we examined the host response to HCV infection by applying gene expression profiling of serial
liver biopsies during acute HCV infection and identified unique gene expression patterns that are associated with specific outcomes of infection.

Results
Hepatic gene expression during early stage of self-limited infection
To identify differentially expressed hepatic genes associated with early stages of HCV infection, a database of expression levels was generated and queried for genes whose expression was outside a calculated 99% confidence interval at different times. Using this confidence interval, 1% of genes with the greatest-fold change or least-fold change are defined as significantly up- or down-regulated (see Materials and Methods). For chimpanzee X0190 with self-limited infection, 347 genes were induced above the confidence interval (>1.9-fold change) at 4 weeks post-infection. Some of the induced genes were related to antiviral and/or type I interferon response, consistent with ongoing HCV infection. To refine our search and to further identify genes specifically associated with the early phase of infection, the database of expression levels for X0190 was queried again for genes above the confidence interval at two time points, weeks 4 and 6 post-infection (>1.9- and >2.1-fold induction), and below the confidence interval at weeks 13 and 40 (<2.2- and <2.4-fold induction) when the chimpanzee had cleared the infection. By using these criteria, 22 genes were significantly up-regulated, of which are known to be induced by type I interferon (Table 1). The remaining 13 genes are classified as Cellular Immune Response Related or Cell Growth/Signal Transduction Related.

Comparison of hepatic gene expression during self-limited and persistent infections
To determine whether a different pattern of gene expression is observed between infected chimpanzees in this subset of genes, biopsy samples from two persistently infected chimpanzees X0234 and X0142 were compared to chimpanzee X0190 (Table 1). Within the first 8 weeks of infection, a large number of type I interferon stimulated genes (ISGs) were strongly up-regulated in all chimpanzees. Type I interferon induced genes are the first line of innate defense against viral infection and also function to prime and modulate adaptive immune response. A qualitative or quantitative difference of ISG induction could not be correlated with persistence or clearance. However several genes related to cellular immune response and cell growth/signal transduction, such as ILF3, TIA1, FOSB, JUN, ID2, were differentially induced in chimpanzee X0190.

At later time points for X0190, none of the type I interferon response genes were significantly upregulated, consistent with the clearance of viremia and resolution of infection. Interestingly, a similar gene expression pattern was also observed for the persistently infected chimp. In X0234, some of these genes that were induced earlier returned to baseline at week 10, but became elevated again at week 12 post-infection. It has been shown that acutely infected chimpanzees and humans can have markedly fluctuating levels of viremia during the acute phase, possibly indicating transient control of viral infection [9-11]. This transient control could explain the lack of continuous induction of ISGs at certain time points. In particular, the viral level of X0234 at week 8 was 4000 genomes/mL, week 10 was 600 genomes/mL (borderline detection), and week 12 was 7000 genomes/mL. Additional biopsy samples from one of these animals, X0142, were collected at much later time points during the chronic phase (Fig. 1). Up-regulation of many ISGs was again observed, suggesting the establishment of chronic infection. This observation is consistent with previous publications [3,6].

As an alternative approach to identify genes induced during the early stage of infection that could be associated with clearance, the average expression profile of persistently infected chimpanzees (X0234 and X0140) was compared to the average expression profile of chimpanzee X0190 during weeks 4 and 6. We reasoned that any difference between the two groups of animals, if significant, might be more easily detected by averaging the gene expression values during this time frame. Furthermore, we might identify a different set of induced genes compared to our previous analysis (e.g. genes whose fold-induction levels were within the confidence interval for at least one time point but were on average higher during the acute phase of infection).

During the first eight weeks of self limited infection (X0190) we found 36 known genes induced 2.5-fold or greater over those during persistent infection (X0234 and X0140). The averaged ratios of induction are shown in Table 2. Six of these genes were also found on the list of the previous analysis of chimpanzee X0190 at weeks 4 and 6 (Table 1).

Hepatic gene expression during the clearance phase of self-limited infection
To identify genes that may be specifically induced during viral clearance in chimpanzee X0190, the database of expression levels was queried for genes above the confidence interval at 13 weeks post-infection (>2.2-fold induction) and below this interval at 4, 6 and 40 weeks (<1.9-, 2.1-, and 2.4-fold induction). Forty-four genes were significantly up-regulated at 13 weeks (Table 3). Twenty of these were associated with activation of cellular immunity and as such were classified as Cellular Immune Response-related. Consistent with the previous observation of active HCV-specific T-cell response in biopsy specimens during resolving infections, we found evidence for a vigorous immune response involving induction of CD8+ T-cell markers (CD8 antigen and components of the T-cell receptor) and effectors of CD8+ T cells (granzyme A and interferon-gamma) in X0190. The remaining 25 genes significantly induced at 13 weeks could be classified as Cell Growth/Signal Transduction-related (Table 3).

To discern additional differences between the self-limited and chronically infected chimpanzees, the averaged expression profiles of the two persistently infected chimpanzees (X0142 and X0234) from weeks 10 to 12 were compared to those of chimpanzee X0190 during clearance (week 13). We reason that viral clearance may be associated with a distinct set of gene expression in the liver. By comparing the gene expression profiles at about the same time when the chimpanzee is undergoing viral clearance to those of chimpanzee who is not could provide valuable insight into the mechanism of viral clearance. During this phase, 20 known genes of X0190 were induced 2.5-fold or greater over the average values of the equivalent time points of X0142 and X0234 (Table 4). Of these, 5 genes are also in Table 3.

Quantitative PCR confirmation of selected genes
To confirm the microarray data, TaqMan real-time PCR was performed on selected genes from each analysis. For ISGs, GIP2 and IFIT1 were analyzed. Among the genes identified in Tables 1 and 2, ILF3, TIA1, ID2 and JUN were selected for quantitative PCR. In addition, serial liver biopsy RNAs from another chimpanzee that developed chronic infection after inoculation with a different HCV strain (H77 1a) were analyzed. The data in general support the microarray results. The ISG expression varied among the chimpanzees, but showed no significant difference between self-limited and chronic infections. The genes (ILF3,
Table 1. Genes induced during the early phase of self-limited and persistent infections.

| Type I Interferon Response | Chimp X0190* | Chimp X0234 | Chimp X0142 |
|----------------------------|--------------|-------------|-------------|
| **Title**                  | Clone description | UG cluster | wk 4 | wk 6 | wk 13 | wk 40 | wk 6 | wk 8 | wk 10 | wk 13 | wk 40 | wk 6 | wk 8 | wk 10 | wk 12 | wk 60 | wk 68 | wk 89 | wk 101 |
| G1P2 | Interferon-stimulated protein (15 kDa) | Hs. 432233 | 8.1 | 4.6 | 0.5 | 0.3 | 5.1 | 7.9 | 1.5 | 0.5 | 7.1 | 14 | 6.7 | 1.5 | 7.9 | 11 | 15 |
| IFI27 | Interferon alpha-inducible protein 27 | Hs. 278613 | 6.6 | 4.4 | 0.6 | 0.3 | 3.5 | 7.1 | 1.5 | 0.6 | 6.6 | 14 | 6.6 | 1.4 | 6.7 | 11 | 14 |
| OAS3 | 2’-5’oligoadenylate synthetase 3 | Hs. 56009 | 5.5 | 5.3 | 1.4 | 0.5 | 3.2 | 2.3 | 1.1 | 0.8 | 4.5 | 4.5 | 2.0 | 1.1 | 4.7 | 4.5 | 4.8 | 4.5 |
| GIP3 | Interferon alpha-inducible protein (clone IFI6-16) | Hs. 265827 | 8.0 | 3.8 | 0.7 | 0.3 | 8.0 | 5.3 | 2.2 | 0.6 | 4.3 | 5.0 | 2.5 | 1.4 | 5.8 | 4.3 | 4.7 | 5.0 |
| IFI1 | Interferon-induced protein w/tetratricopeptide repeat | Hs. 20315 | 3.8 | 2.8 | 0.6 | 0.9 | 3.2 | 6.4 | 0.9 | 0.5 | 4.3 | 4.9 | 6.6 | 0.6 | 6.8 | 4.3 | 5.3 | 4.9 |
| MK1 | Myxovirus (influenza) resistance 1 | Hs. 48516 | 3.6 | 3.8 | 1.0 | 0.7 | 3.1 | 2.8 | 1.0 | 1.5 | 3.4 | 2.8 | 1.8 | 0.8 | 4.2 | 3.4 | 3.7 | 2.8 |
| B2M | Beta-2-microglobulin | Hs. 75415 | 3.2 | 2.2 | 1.4 | 0.8 | 0.8 | 3.9 | 2.4 | 0.6 | 2.3 | 2.2 | 2.2 | 1.2 | 2.5 | 2.3 | 2.4 | 2.2 |
| OAS2 | 2’-5’oligoadenylate synthetase 2 | Hs. 432659 | 2.7 | 2.2 | 1.0 | 0.8 | 2.0 | 2.0 | 1.1 | 1.1 | 3.2 | 2.2 | 2.1 | 1.3 | 1.1 | 1.3 | 0.9 | 1.1 |
| SP110 | Interferon-induced protein 75 (52 kD) | Hs. 38125 | 2.7 | 2.3 | 1.3 | 0.7 | 1.4 | 0.9 | 1.3 | 0.8 | 1.8 | 1.3 | 1.3 | 1.3 | 3.3 | 3.2 | 2.4 | 2.2 |

**Cellular Immune Response**

| **Title** | Clone description | UG cluster | wk 4 | wk 6 | wk 13 | wk 40 | wk 6 | wk 8 | wk 10 | wk 12 |
|------------|------------------|-------------|-----|-----|-----|-----|-----|-----|-----|-----|
| ILF3 | Interleukin enhancer binding factor 3, 90 kD | Hs. 56583 | 3.0 | 2.3 | 1.6 | 0.8 | 1.5 | 0.9 | 1.7 | 1.1 |
| TIA1 | Cytotoxic granule-associated RNA-binding protein | Hs. 39489 | 2.6 | 2.2 | 2.1 | 1.0 | 1.3 | 0.6 | 1.1 | 1.1 |

**Cell Growth/Signal Transduction**

| **Title** | Clone description | UG cluster | wk 4 | wk 6 | wk 13 | wk 40 | wk 6 | wk 8 | wk 10 | wk 12 |
|------------|------------------|-------------|-----|-----|-----|-----|-----|-----|-----|-----|
| FO85 | FBJ murine osteosarcoma viral oncogene homolog B | Hs. 75678 | 10 | 5.4 | 0.4 | 0.3 | 0.7 | 0.4 | 0.7 | 1.2 |
| SMARC8 | Actin dependent regulator of chromatin (SW/SNF related) | Hs. 59971 | 7.9 | 4.5 | 0.6 | 0.5 | 1.1 | 1.1 | 1.0 | 0.9 |
| ITGAI | Integrin alpha 6 | Hs. 27730 | 6.6 | 3.4 | 1.4 | 0.6 | 0.7 | 1.2 | 1.3 | 1.3 |
| JUN | v-jun avian sarcoma virus 17 oncogene homolog | Hs. 78465 | 4.7 | 3.3 | 0.3 | 0.6 | 0.9 | 0.9 | 1.0 | 0.9 |
| PRNP | Prion protein (p27-30) | Hs. 74621 | 3.6 | 2.1 | 2.1 | 2.0 | 0.7 | 1.7 | 1.3 | 0.6 |
| ID2 | Inhibitor of DNA binding 2 | Hs. 180919 | 3.1 | 2.2 | 0.5 | 0.6 | 0.6 | 0.9 | 0.7 | 0.8 |
| JUNB | Jun B proto-oncogene | Hs. 400124 | 3.0 | 2.8 | 1.7 | 1.3 | 1.1 | 0.8 | 1.0 | 1.3 |
| TOBI | Transducer of ERBB2 | Hs. 4994 | 2.8 | 2.3 | 1.9 | 0.6 | 1.9 | 1.4 | 1.7 | 2.3 |
| PRSS21 | Serine protease, 21 (testisin) | Hs. 72026 | 2.5 | 2.5 | 1.6 | 1.0 | 2.3 | 2.2 | 1.8 | 1.7 |
| TRB2 | Ras homolog gene family, member | Hs. 15114 | 2.0 | 2.4 | 0.8 | 0.8 | 0.9 | 0.8 | 0.9 | 1.1 |
| AHRD | Ras homolog gene family, member | Hs. 15114 | 2.0 | 2.4 | 0.8 | 0.8 | 0.9 | 0.8 | 0.9 | 1.1 |

Confidence interval 1.9 2.1 2.2 2.4 2.5 2.0 2.6 2.4 2.5 2.0 2.6 2.4 2.2 2.5 1.9 2.0

*Expression levels of genes induced above the confidence interval at weeks 4 & 6 but below the confidence interval at weeks 13 & 40 in X0190.
The bold and italicized values represent data above the 99% confidence interval as described in the text.
doi:10.1371/journal.pone.0003442.t001
TIA1, ID2 and JUN) identified to be different by microarray during the early phase of HCV infection between the two groups were confirmed by quantitative PCR. Their expression levels were 10 to 100-fold higher in X0190 than those of other three chimpanzees.

Discussion

HCV infection can lead to a high rate of chronicity, with 70–80% of infected persons developing persistent infection [1]. The mechanisms by which HCV establishes chronic infection have been the subject of intense research. Failure of HCV-specific immune response, particularly of the T cells, has been proposed as the cause of chronicity [12,13]. Studies in humans and chimpanzees have shown that T cell-mediated immunity is important for viral clearance [14,15]. However, the pivotal question remains as to how the host immune response fails during the acute HCV infection so it can no longer control the virus, resulting in persistent infection. Thus it is crucial to define the molecular and cellular mechanisms by which the antiviral host response is activated and regulated during the early stage of acute HCV infection. Furthermore, because the major site of viral tropism is the liver, it is essential to study these events in the liver. One approach to elucidate this complicated process is to study the global gene expression profile in the liver during the acute phase of viral infection, and to discern unique patterns that are associated with either viral clearance or progression to chronic infection.

We previously reported the infection of three chimpanzees with an infectious HCV genotype 1b clone; one had acute self-limited infection and the other two developed chronic infection [16]. We reported that regardless of the outcome of infection, peripheral T-cell responses were weak and comparable among the chimpanzees during the course of infection; however, intrahepatic T-cell response was not analyzed [17]. In this study, serial liver biopsies were available in these chimpanzees and were used for cDNA microarray analysis. Analysis of these gene expression patterns revealed that a type I interferon response was induced during the early phase (4–8 weeks) of infection in all chimpanzees regardless of the outcome of infection. Various well-defined interferon stimulated genes were up-regulated in all the liver samples. This observation is consistent with previous studies describing that type I interferon response is rapidly induced in the liver in response to HCV infection [2,6].

Interestingly, several genes were specifically induced in the recovered chimpanzee during the early phase of infection but not in those chimpanzees with chronic infection. Two of the genes are interleukin enhancer binding factor 3 (ILF3) and cytotoxic granule-associated RNA binding protein (TIA1). This difference was also confirmed by quantitative RT-PCR (Fig. 2). Both of them are related to cellular immune response and may potentially herald the emergence of a robust T-cell response later. The other genes could be functionally clustered into cell growth/signal transduction pathways. Genes such as FOSB, JUN, JUNB, and ID2 (Tables 1 and 2) are typically associated with the immediate early genes during liver regeneration [18,19]. Several studies reported that ID2 (Inhibitor of DNA binding or Differentiation) protein, a helix-loop-helix transcription factor, has important roles in cell growth, differentiation and angiogenesis [20,21]. ID2 is also essential for NK lineage commitment from bipotent progenitors of both T and NK cells [22]. Other up-regulated genes including EGR1, ETR101, CDK9 and RelA, are also related to cell growth and proliferation [23–25]. Induction of EGR1 and ETR101 is also part of the early proliferative response in the liver. In addition, EGR1 is involved in the induction of FasL in T cells [26] and the ETR101 has been implicated in T cell proliferation and maturation [27]. These two genes might represent the induction of a successful T cell response against HCV in chimpanzees X0190 but not in X0142 and X0234. The induction of these genes may signify the initial phase of hepatocyte injury and proliferation, despite the absence of aminotransferase elevation and liver pathology during this stage of infection. This observation has implication with respect to the induction of adaptive immunity that is important for the subsequent control of viral infection. This pattern of gene expression in the liver may represent a successful “danger signal” that has been proposed to be a trigger for adaptive immunity. The lack of induction of these genes in chimpanzees

Figure 1. Chimpanzee inoculation and biopsy schedule. Chimpanzees were inoculated with RNA transcript of the molecular clone HCV-CG1b or infectious serum from the same clone (○). The course of infection has been described previously (Thomson et al., 2001). The level of viremia is shown as either positive (+) negative (−). Biopsy samples were taken at various time points after inoculation ( □ ) and used for microarray analysis X0190, X0234 and X0142. RNA samples from weeks 8 and 10 of X0190 were not of adequate quality for microarray analysis.
doi:10.1371/journal.pone.0003442.g001
that progress to chronic infection may actually represent a failure to amplify anti-viral T-cell response. This intriguing hypothesis awaits further studies to clarify the role of these genes during HCV infection.

During acute HCV infection, a rapid IFN response limits virus replication and spread in the liver until virus-infected hepatocytes are cleared by specific T-cell immune response [3]. Analysis of gene expression patterns during the viral clearance phase of chimpanzee X0190 reveals the intrahepatic induction of cellular immune response. This is particularly evident with markers of CD8+ T cell response including granzyme A, CD8 antigen, T cell receptors, and interferon-gamma (Table 3). On the other hand, fewer of these genes were induced and at a lower magnitude in chimpanzees with chronic infection. These findings are consistent with a recent study on hepatic gene expression in chimpanzees during acute HCV infection [2,6], and support the importance of T cell immune response in controlling HCV infection [28–33,12,34,7]. Other genes that were preferentially induced during the clearance phase are diverse. They do not overlap with those genes induced during the early phase of infection and may

Table 2. Genes induced during the early phase of self-limited infection as defined by average expression values.

| Title | Clone description | UG cluster | Self-limited infection* | Persistent infection* | Ratio of induction |
|-------|-------------------|------------|-------------------------|-----------------------|-------------------|
| FOSB  | FBX murine osteosarcoma viral oncogene homolog B | Hs.75678 | 7.54 | 0.77 | 9.77 |
| DCT   | Dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2) | Hs.301865 | 6.55 | 0.69 | 9.44 |
| SMARCB| Actin dependent regulator of chromatin (SWI/SNF related) | Hs.159971 | 6.04 | 0.64 | 9.41 |
| EGR1  | Early growth response 1 | Hs.738 | 2.50 | 0.30 | 8.20 |
| ETR101| Immediate early protein | Hs.737 | 8.02 | 1.19 | 6.75 |
| RP54Y | Ribosomal protein S4, Y-linked | Hs.180911 | 8.46 | 1.40 | 6.02 |
| JUN   | v-jun avian sarcoma virus 17 oncogene homolog | Hs.78465 | 3.99 | 0.76 | 5.21 |
| CYP1A1| Cytochrome P450, subfamily 1 (aromatic compound-inducible), polypeptide 1 | Hs.72912 | 2.18 | 0.48 | 4.51 |
| SCYA3 | Small inducible cytokine A3 (homologous to mouse Mip-1a) | Hs.73817 | 1.23 | 0.29 | 4.28 |
| PEX1  | Peroxisome biogenesis factor 1 | Hs.99847 | 3.68 | 0.90 | 4.09 |
| KIAA0855| Golgin-67 | Hs.182982 | 2.01 | 0.54 | 3.75 |
| SARS  | Seryl-tRNA synthetase | Hs.4888 | 1.13 | 0.31 | 3.68 |
| GLO1  | Glyoxalase I | Hs.75207 | 4.14 | 1.14 | 3.63 |
| ITGA6 | Integrin alpha 6 | Hs.227730 | 4.79 | 1.35 | 3.55 |
| DUSP1 | Dual specificity phosphatase 1 | Hs.171695 | 2.31 | 0.68 | 3.41 |
| PRNP  | Prion protein (p27–30) | Hs.74621 | 2.79 | 0.87 | 3.21 |
| RUVBL2| RuB (E coli homolog)-like 2 | Hs.6455 | 1.80 | 0.58 | 3.10 |
| SCYA3L| Small inducible cytokine A3-like 1 | Hs.274535 | 0.97 | 0.31 | 3.10 |
| TRF4  | Topoisomerase-related function protein 4-1 | Hs.225951 | 1.73 | 0.57 | 3.03 |
| CALML3| Calmodulin-like 3 | Hs.239600 | 2.96 | 1.01 | 2.94 |
| GCN1L1| GCN1 (general control of amino-acid synthesis 1, yeast)-like 1 | Hs.75354 | 1.58 | 0.55 | 2.89 |
| SCD   | Stearoyl-CoA desaturase (delta-9-desaturase) | Hs.119597 | 1.16 | 0.40 | 2.88 |
| ATP2B2| ATPase, Ca++ transporting, plasma membrane 2 | Hs.89512 | 1.40 | 0.49 | 2.86 |
| CYP4F3| Cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4 omega hydroxylase) | Hs.106242 | 2.94 | 1.05 | 2.80 |
| COL7A1| Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) | Hs.1640 | 1.58 | 0.57 | 2.78 |
| SLC6A3| Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | Hs.406 | 2.57 | 0.95 | 2.70 |
| KLF4  | Kruppel-like factor 4 (gut) | Hs.7934 | 2.23 | 0.83 | 2.67 |
| ILF3  | Interleukin enhancer binding factor 3, 90 kD | Hs.256583 | 2.63 | 1.00 | 2.62 |
| ID2   | Inhibitor of DNA binding 2 | Hs.180919 | 2.64 | 1.02 | 2.58 |
| ZNF216| Zinc finger protein 216 | Hs.3776 | 1.07 | 0.41 | 2.57 |
| NR1I2 | Nuclear receptor subfamily 1, group L, member 2 | Hs.118138 | 1.89 | 0.74 | 2.56 |
| TIA1  | TIA1 cytotoxic granule-associated RNA-binding protein | Hs.239489 | 2.40 | 0.94 | 2.56 |
| CDK9  | Cyclin-dependent kinase 9 (CDC2-related kinase) | Hs.150423 | 1.66 | 0.66 | 2.52 |
| RELA  | v-rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypepti | Hs.75569 | 1.79 | 0.71 | 2.52 |
| EPHX2 | Epoxide hydrolase 2, cytoplasmic | Hs.113 | 2.50 | 1.00 | 2.51 |
| CYP4F2| Cytochrome P450, subfamily IVF, polypeptide 2 | Hs.101 | 1.99 | 0.79 | 2.51 |

*Average expression values of biopsies taken during the 1st 8 weeks of infection. Bold-face genes are also in Table 1.

doi:10.1371/journal.pone.0003442.t002
| Gene          | Description                                      | Chimp X0190* | Chimp X0234 | Chimp X0142 |
|---------------|--------------------------------------------------|--------------|-------------|-------------|
| GZMA          | Granzyme A                                       | 1.3          | 1.7         | 6.5         |
| CD3D          | CD3D antigen, delta polypeptide                   | 1.7          | 2.0         | 6.4         |
| IGL           | Immunoglobulin lambda locus                       | 1.7          | 1.8         | 2.1         |
| CD8B1         | CD8 antigen, beta polypeptide 1 (p37)             | 1.4          | 1.8         | 3.6         |
| CCL5          | Small inducible cytokine A5 (RANTES)              | 0.9          | 1.1         | 4.8         |
| TRA           | Human T-cell receptor active alpha-chain          | 1.8          | 1.7         | 1.4         |
| CSF2RA        | Colony stimulating factor 2 receptor             | 1.3          | 1.9         | 4.0         |
| KLRB1         | Killer cell lectin-like receptor subfamily B     | 1.9          | 2.1         | 3.9         |
| CD8A          | CD8 antigen, alpha polypeptide (p32)              | 1.6          | 1.4         | 3.5         |
| IGHG3         | Immunoglobulin heavy constant gamma 3            | 1.6          | 1.6         | 3.4         |
| CD2           | CD2 antigen (p50)                                | 1.9          | 1.3         | 3.3         |
| TRGV9         | T cell receptor gamma locus                      | 1.2          | 1.9         | 3.0         |
| ITK           | IL2-inducible T-cell kinase                      | 1.7          | 1.7         | 3.0         |
| SELPLG        | Selectin P ligand                                | 1.5          | 1.6         | 2.8         |
| VIL2          | Villin 2 (ezrin)                                 | 1.1          | 1.8         | 2.4         |
| RIS8          | Retinoic acid- and interferon-inducible protein  | 0.7          | 0.9         | 2.4         |
| IFNG          | Interferon gamma                                 | 1.2          | 1.6         | 2.4         |
| TANK          | TRAF family member-associated NFKB activator     | 1.3          | 1.5         | 2.3         |
| TNFRSF1A      | Tumor necrosis factor receptor (1A)              | 1.6          | 1.2         | 2.3         |
| PADI4         | Peptidyl arginine deaminase (type IV)            | 0.8          | 1.3         | 2.2         |
| SFTPA2        | Surfactant (pulmonary-associated protein A1)     | 1.2          | 1.4         | 3.6         |
| UBD           | Dicubquitin                                       | 0.9          | 0.6         | 3.5         |
| HoxB5         | Homeo box B5                                     | 1.1          | 1.7         | 3.2         |
| BAZ2B         | Bromodomain adjacent to zinc finger domain, 28   | 1.6          | 1.2         | 3.0         |
| A1IQ1         | ALL1-fused gene from chromosome 1q              | 1.8          | 2.0         | 2.6         |
| ITM2A         | Integral membrane protein 2A                     | 1.0          | 1.4         | 2.6         |
| ANXA6         | Annexin A                                        | 1.0          | 1.4         | 2.5         |
| SFRS3         | Splicing factor, arginine/serine-rich 3          | 1.8          | 1.8         | 2.5         |
| AMY2A         | Amylase, alpha 2A; pancreatic                     | 1.2          | 1.6         | 2.5         |
| KIF22         | Kinesin-like 4                                    | 1.4          | 0.9         | 2.5         |
| CAPON         | Ligand of neuronal nitric oxide synthase         | 1.7          | 1.6         | 2.5         |
| COX1B         | Cytochrome c oxidase (subunit Vb)                | 1.4          | 1.0         | 2.5         |
| LGALS1        | Galactoside-binding lectin (galectin 1)          | 1.6          | 1.2         | 2.4         |
Table 3. cont.

| Cellular Immune Response | Chimp X0190 | Chimp X0234 | Chimp X0142 |
|--------------------------|------------|------------|------------|
| Title                    | Clone description | UG cluster | wk 4 | wk 6 | wk 13 | wk 40 | wk 6 | wk 8 | wk 10 | wk 12 | wk 6 | wk 8 | wk 10 | wk 12 | wk 60 | wk 68 | wk 89 | wk 101 |
| MBL1P1                   | Mannose-binding lectin, pseudogene 1 | Hs.116218 | 1.7  | 1.6  | 2.4  | 1.6  | 1.2  | 0.6  | 0.8  | 1.1  | 1.4  | 2.4  | 0.8  | 2.1  | 1.1  | 1.4  | 1.3  | 2.4  |
| GNG3                     | Guanine nucleotide binding protein | Hs.179915 | 1.5  | 1.4  | 2.4  | 2.1  | 1.7  | 1.7  | 2.4  | 2.9  | 1.7  | 1.2  | 1.3  | 2.3  | 2.0  | 1.7  | 1.8  | 1.2  |
| RBBP4                    | Retinoblastoma-binding protein 4 | Hs.16003 | 1.2  | 1.3  | 2.4  | 1.7  | 1.2  | 1.1  | 1.0  | 1.7  | 1.7  | 1.2  | 1.7  | 1.2  | 1.4  | 1.4  | 1.7  | 1.4  | 1.2  |
| CHI3L1                   | Chitinase 3-like 1 (cartilage glycoprotein-39) | Hs.75184 | 0.9  | 1.6  | 2.4  | 1.9  | 1.5  | 1.5  | 1.1  | 2.7  | 1.2  | 1.6  | 0.9  | 0.9  | 2.3  | 1.2  | 1.1  | 1.6  |
| NESG1                    | Nasopharyngeal epithelium specific protein 1 | Hs.159450 | 0.6  | 1.5  | 2.3  | 1.6  | 1.1  | 1.1  | 0.8  | 3.2  | 1.2  | 1.2  | 0.7  | 1.1  | 2.5  | 1.2  | 1.0  | 1.2  |
| CBLC                     | Cas-Br-M Murine retroviral transforming | Hs.156637 | 0.6  | 1.5  | 2.3  | 1.6  | 1.2  | 0.9  | 0.8  | 3.7  | 1.5  | 1.4  | 1.2  | 1.1  | 3.8  | 1.5  | 1.8  | 1.4  |
| SLC21A6                  | Solute carrier family 21 | Hs.137425 | 1.4  | 1.1  | 2.3  | 1.1  | 3.5  | 0.6  | 1.8  | 4.3  | 1.1  | 1.3  | 0.5  | 1.4  | 1.0  | 1.1  | 1.2  | 1.3  |
| DSS1                     | Deleted in split-hand/split-foot 1 region | Hs.333495 | 1.2  | 1.0  | 2.3  | 1.5  | 1.2  | 1.2  | 1.2  | 1.1  | 1.8  | 1.2  | 2.2  | 1.0  | 1.4  | 1.4  | 1.5  | 1.2  |
| BAIAP1                   | BAI1-associated protein 1 | Hs.169441 | 1.1  | 1.3  | 2.3  | 1.2  | 1.2  | 8.0  | 1.1  | 1.4  | 1.8  | 2.0  | 0.7  | 1.4  | 1.3  | 1.8  | 1.3  | 2.0  |
| PCAF                     | PCAF associated factor 65 beta | Hs.26782 | 1.7  | 1.7  | 2.2  | 1.3  | 2.2  | 2.4  | 2.8  | 2.1  | 1.3  | 0.9  | 0.8  | 1.1  | 1.1  | 1.3  | 0.7  | 0.9  |
| EIF2AK3                  | Eukaryotic translation initiation factor 2-alpha kinase 3 | Hs.102506 | 1.5  | 1.4  | 2.2  | 1.3  | 1.0  | 0.9  | 0.8  | 1.1  | 1.3  | 1.1  | 0.8  | 2.1  | 1.0  | 1.3  | 1.2  | 1.1  |
| 99% confidence interval  |                             |           | 1.9  | 2.1  | 2.2  | 2.4  | 2.1  | 2.7  | 2.0  | 3.3  | 2.5  | 2.0  | 2.6  | 2.4  | 2.2  | 2.5  | 1.9  | 2.0  |

*Expression levels of genes induced above the confidence interval at week 13 but below the confidence interval at weeks 4, 6 & 40 of X0190.
The bold and italicized values represent data above the 99% confidence interval as described in the text.
doi:10.1371/journal.pone.0003442.t003
represent a more complex array of molecular and cellular events during viral clearance. All these genes returned to baseline expression after viral clearance. In contrast, many ISGs remained elevated in chimpanzees with chronic infection, indicating an ongoing type I IFN response to persistent HCV infection.

In this study, molecular profiling of gene expression patterns in chimpanzees with serial liver biopsies during the course of infection provides valuable information on the potential mechanisms of viral clearance and persistence. Although the number of animals is small, we are able to define a unique gene expression pattern associated with viral clearance and demonstrate the potential importance of induction of certain genes in a “successful” anti-HCV response. IFN-stimulated genes (ISGs) are induced similarly regardless of the outcome of infection. Early induction of a set of genes associated with cell proliferation and immune activation appears to be involved in subsequent viral clearance. Furthermore, evidence for a strong intrahepatic induction of cellular immune response in chimpanzees associated with self-limited infection is present. These findings support the importance of T-cell immune response in controlling HCV infection. Additional studies in other chimpanzees or humans with well-characterized course of acute infection are necessary to confirm these observations.

## Materials and Methods

### Animals

Chimpanzees (*Pan troglodyte*) were housed at the Southwest Foundation for Biomedical Research, an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility, and the study protocol was approved by the Institutional Animal Care and Use Committee at the Foundation and by the Interagency Animal Model Committee at the National Institutes of Health. Three chimpanzees (X0190, X0142 and X0234) were infected with HCV CG1b strain, either by intrahepatic inoculation of HCV RNA or HCV-positive serum, as described previously [16]. One animal X0190 recovered from the infection and the other two (X0142 and X0234) developed chronic infection. The infection courses of all three chimpanzees have been described in detail previously [16,17] and summarized in Fig. 1 with time points of liver biopsy.

Another chimpanzee X6412 was infected with H77 1a strain and developed chronic infection [35]. Serial liver biopsies of this chimpanzee were provided by Stephen Feinstone of FDA.

## RNA extraction and microarray expression analysis

RNA was isolated from liver biopsies (about 20 mg of liver tissue which gives 10–15 µg of total RNA) of the chimpanzees. Deposition cDNA microarrays containing 8703 features were generated from IMAGE clones (ResGen, Huntsville, AL) as described previously [36,37]. Liver biopsies were extracted directly with Trizol (Invitrogen, Carlsbad, CA) and Dounce homogenization. Following chloroform extraction, RNA samples were further purified with RNeasy columns (Qiagen, Valencia, CA). 5–20 µg total RNA was typically isolated from each liver biopsy and 5 µg of RNA was amplified using a RiboAmp protocol (Arcturus Bioscience Inc, Mountain View, California). A single round of amplification yielded approximately 60 µg of polyA-selected RNA, of which 2.5 µg was labeled by using the CyScribe first-strand cDNA and labeling protocol (Amersham/Pharmacia,

### Table 4. Genes induced during the clearance phase of self-limited infection as defined by average expression values

| Title | Clone description | UG cluster | Self-limited infection* | Persistent infection* | Ratio of induction |
|-------|-------------------|------------|------------------------|----------------------|-------------------|
| RPS4Y | Ribosomal protein S4, Y-linked | Hs.180911 | 12.66 | 1.64 | 7.72 |
| GLO1  | Glyoxalase I       | Hs.268849 | 4.07 | 0.75 | 5.41 |
| NPTX1 | Neuronal pentraxin I | Hs.84154  | 1.45 | 0.40 | 3.59 |
| RIS8  | Retinoic acid- and interferon-inducible protein (58 kD) | Hs.252839 | 2.40 | 0.70 | 3.42 |
| UK114 | Translational inhibitor protein p14.5 | Hs.18426 | 2.00 | 0.59 | 3.40 |
| AMHR2 | Anti-Mullerian hormone receptor, type II | Hs.437877 | 0.97 | 0.30 | 3.19 |
| CD8B1 | CD8 antigen, beta polypeptide 1 (p37) | Hs.2299 | 5.57 | 1.76 | 3.16 |
| KLRB1 | Killer cell lectin-like receptor subfamily B, member 1 | Hs.169824 | 3.89 | 1.24 | 3.13 |
| APOF  | Apolipoprotein F    | Hs.2388  | 1.00 | 0.32 | 3.12 |
| KIAA0855 | Golgin-67         | Hs.182982 | 1.60 | 0.54 | 2.95 |
| TSNAX | Translin-associated factor X | Hs.96247 | 1.81 | 0.63 | 2.89 |
| FKBP5 | FK506-binding protein 5 | Hs.7557 | 2.69 | 0.94 | 2.87 |
| NNMT  | Nicotinamide N-methyltransferase | Hs.364345 | 2.07 | 0.76 | 2.73 |
| NUP153 | Nucleoporin 153 KD | Hs.146449 | 1.95 | 0.72 | 2.71 |
| SOCS3 | Suppressor of cytokine signaling 3 | Hs.436943 | 2.54 | 0.94 | 2.69 |
| CD3D  | CD3D antigen, delta polypeptide | Hs.95327 | 6.44 | 2.42 | 2.66 |
| CALML3 | Calmodulin-like 3 | Hs.239600 | 3.37 | 1.28 | 2.63 |
| ARF3  | Human ADP-ribosylation factor | Hs.22012 | 1.40 | 0.54 | 2.58 |
| GZMA  | Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) | Hs.90708 | 6.48 | 2.56 | 2.53 |

*Expression value of biopsy taken at 13 weeks of infection.

Average expression values of biopsies taken during the 10 and 12 weeks of infection.

Bold-face genes are also in Table 1.

[doi:10.1371/journal.pone.0003442.t004](#)
Figure 2. Real-time PCR quantification of candidate genes involved in viral clearance and persistence. TaqMan real-time PCR was performed as described in Materials and Methods. The y-axis shows the relative unit of a given gene normalized to GAPDH and 18s rRNA. Data are expressed as means ± SEM. In all cases, average values obtained during the first eight weeks of infection were compared between recovered (X0190) and chronically infected chimpanzees (X0234, X0142, and X6412). * P < 0.05, ** P < 0.01, *** P < 0.01, **** P < 0.005.

doi:10.1371/journal.pone.0003442.g002
Piscataway, New Jersey). Briefly, RNA was reverse transcribed to produce Cy-5 labeled cDNA while Cy-3 labeled cDNA was made in a similar manner from pre-infection or uninfected reference liver RNA. Individual Cy-5 labeled samples were mixed with the Cy-3 labeled reference and hybridized overnight at 65°C in an aqueous based hybridization solution. Detailed RNA isolation, labeling and hybridization protocols are available at http://research.nhgri.nih.gov/microarray/. Slide images were acquired by an Agilent scanner (Agilent Technologies, Palo Alto, CA). Gene assignments and expression data were extracted using the DeArray Suite [38] for IPLab spectrum. The resulting data was downloaded to FileMaker Pro (FileMaker Inc., Santa Clara, CA). Phenotype averaging was performed using the BRB array tools, developed by the Biometrics Research Branch, Division of Cancer Treatment and Diagnosis and available to download on the web: http://limus.nci.nih.gov/BRB-ArrayTools.html

Real-time Quantitative PCR

Real-time quantitative PCR was used to confirm the microarray findings. Complementary DNA (cDNA) was synthesized from total RNA (isolated from liver biopsy samples) with First-strand cDNA Synthesis System (Marligen Biosciences, Ijamsville, MD). In addition, we analyzed serial liver biopsy samples from a chronically infected chimpanzee (X1602, infected with genotype 1a H77 strain) by TaqMan PCR quantification of selected genes of interest. The primers and probes used were obtained from Gene Expression Assays (Applied Biosystems, Foster City, CA). Each reaction was performed in duplicate, and all samples were standardized using the internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene and 18S rRNA. Reactions were set up with 12.5 μl TaqMan universal PCR master mix, cDNA template, and 1.25 μl primers and probe mix in a final volume of 25 μl. Reactions were performed on an iCycler IQ Multicolor Real-Time Detection System (Bio-Rad, Hercules, CA) with the following reaction conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 20 sec, 60°C for 1 min, and additional incubation at 68°C for 10 min.

Statistical Analysis

The overall significance was assessed by 1-way ANOVA and significant difference between groups was assessed by the Student’s t-test.

Acknowledgments

We would like to thank Krishna Murthy and the veterinary staff of the Southwest Foundation for Biomedical Research for conducting the chimpanzee experiment, Stephen Feinstone for providing the additional chimpanzee materials, and the NIAMS microarray facility for data acquisition and analysis.

Author Contributions

Conceived and designed the experiments: SKN MBH TJL. Performed the experiments: SKN MBH GMC. Analyzed the data: SKN MBH TJL. Contributed reagents/materials/analysis tools: MT CJJ DK. Wrote the paper: SKN. As a team leader, managed the group to be on task: TJL.

References

1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH (2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132: 296–305.
2. Bigger CB, Brasky KM, Lanford RE (2001) DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 75: 7059–66.
3. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, et al. (2004) Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 78: 15779–92.
4. Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR (2005) Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 42: 702–10.
5. Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, et al. (2003) Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 38: 1458–67.
6. Su AI, Pezacki JP, Wodicka L, Bridae AD, Supeova L, et al. (2002) Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 99: 15669–74.
7. Thimme R, Oldhac D, Chang KM, Sieger C, Ray SG, et al. (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194: 1395–406.
8. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, et al. (2002) Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 99: 15661–8.
9. Fernandez J, Taylor D, Morhardt DR, Mihalik K, Puig M, et al. (2004) Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J Virol 78: 9769–82.
10. Rahman F, Helser T, Soboa Y, Muzkoshi E, Nascimbeni M, et al. (2004) Effects of viral load on the cellular immune response in acute hepatitis C. Hepatology 40: 87–97.
11. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R, et al. (2005) Thresholds and Relative Importance of CD4 Help. J Virol 82: 1827–37.
12. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R, et al. (2005) The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77: 862–70.
13. Rahman F, Helser T, Soboa Y, Muzkoshi E, Nascimbeni M, et al. (2005) Effects of viral load on the cellular immune response in acute hepatitis C. Hepatology 40: 87–97.
14. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R, et al. (2005) The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77: 862–70.
15. Rahman F, Helser T, Soboa Y, Muzkoshi E, Nascimbeni M, et al. (2005) Effects of viral load on the cellular immune response in acute hepatitis C. Hepatology 40: 87–97.
16. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R, et al. (2005) The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77: 862–70.
17. Rahman F, Helser T, Soboa Y, Muzkoshi E, Nascimbeni M, et al. (2005) Effects of viral load on the cellular immune response in acute hepatitis C. Hepatology 40: 87–97.
18. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R, et al. (2005) The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77: 862–70.
19. Rahman F, Helser T, Soboa Y, Muzkoshi E, Nascimbeni M, et al. (2005) Effects of viral load on the cellular immune response in acute hepatitis C. Hepatology 40: 87–97.
20. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R, et al. (2005) The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77: 862–70.
21. Rahman F, Helser T, Soboa Y, Muzkoshi E, Nascimbeni M, et al. (2005) Effects of viral load on the cellular immune response in acute hepatitis C. Hepatology 40: 87–97.
22. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R, et al. (2005) The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77: 862–70.
23. Rahman F, Helser T, Soboa Y, Muzkoshi E, Nascimbeni M, et al. (2005) Effects of viral load on the cellular immune response in acute hepatitis C. Hepatology 40: 87–97.
24. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R, et al. (2005) The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77: 862–70.
25. Rahman F, Helser T, Soboa Y, Muzkoshi E, Nascimbeni M, et al. (2005) Effects of viral load on the cellular immune response in acute hepatitis C. Hepatology 40: 87–97.
26. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R, et al. (2005) The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77: 862–70.
27. Rahman F, Helser T, Soboa Y, Muzkoshi E, Nascimbeni M, et al. (2005) Effects of viral load on the cellular immune response in acute hepatitis C. Hepatology 40: 87–97.
28. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R, et al. (2005) The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77: 862–70.
29. Cucchiarini M, Kammer AR, Grabscheid B, Diepolder HM, Gerlach TJ, et al. (2000) Vaginous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 203: 111–23.
30. Diepolder HM, Zachoval R, Hoffmann RM, Jung MC, Gerlach T, et al. (1996) The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. J Mol Med 74: 583–8.
31. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, et al. (1995) Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346: 1006–7.
32. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, et al. (1999) Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 117: 933–41.
33. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, et al. (2000) Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191: 1499–512.
34. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, et al. (2000) Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6: 578–82.
35. Major ME, Dahari H, Mihalik K, Puig M, Rice CM, et al. (2004) Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 39: 1709–20.
36. Khan J, Bittner ML, Chen Y, Meltzer PS, Trent JM (1999) DNA microarray technology: the anticipated impact on the study of human disease. Biochim Biophys Acta 1423: M17–28.
37. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, et al. (1998) Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 58: 5069–73.
38. Chen Y, Dougherty ER, Bittner ML (1997) Ratio-based decisions and the quantitative analysis of cDNA microarray images. J Biomed Opt 2: 364–374.